LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL0285 | Name | CCND1 | Aliases | BCL1; D11S287E; PRAD1; U21B31 | |
Species | Homo sapiens | Chromosome | 11 | Start site | 69641087 | |
End site | 69654474 | Chain | plus | Exon NO. | 5 | |
Assembly | Ensembl Release 89 | Class | retained intron | NCBI accession | N/A | |
Ensembl | ENSG00000110092 | Sequence | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
tumor | N/A | N/A | N/A | regulation | Binding to TLS protein induces TLS allosteric change, allowing interaction with cyclin D1, inhibiting CBP and p300 activity, and silencing cyclin D1 gene expression. | 22996375 | LncRNADisease | ||
cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer | ||